Research programme: albumin fusion proteins - Dyax
Latest Information Update: 01 Aug 2012
At a glance
- Originator Dyax
- Class Albumins; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 01 Aug 2012 No development reported for Undefined indication in United Kingdom (unspecified route)
- 15 May 2008 Early research in Undefined indication in United Kingdom (unspecified route)